Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Xiao Fang Pharmaceutical Co EBITDA Margin %?
Shanghai Xiao Fang Pharmaceutical CoSHSE:603207 +1.72%38 EBITDA Margin % is 44.94% as of Mar. 2026, which is 10% below its 10-year median of 49.96. GuruFocus rates SHSE:603207 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 960 Drug Manufacturers companies, Shanghai Xiao Fang Pharmaceutical Co ranks better than 95.42% on this metric.
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Xiao Fang Pharmaceutical Co EBITDA Margin % Related Terms
Shanghai Xiao Fang Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Xiao Fang Pharmaceutical Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Xiao Fang Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Xiao Fang Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Xiao Fang Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Xiao Fang Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) has a EBITDA Margin % of 44.94% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Xiao Fang Pharmaceutical Co and its competitors. This is 10% below median its historical median of 49.96. Over the past decade, Shanghai Xiao Fang Pharmaceutical Co's EBITDA Margin % has ranged from 39.88 to 52.86. According to the industry distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #44 out of 960 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is Shanghai Xiao Fang Pharmaceutical Co's EBITDA Margin % too high?
Shanghai Xiao Fang Pharmaceutical Co's current EBITDA Margin % of 44.94% is 10% below median its 10-year median of 49.96. Over the past 10 years, this metric has ranged from a low of 39.88 to a high of 52.86. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Shanghai Xiao Fang Pharmaceutical Co's value of 44.94% is 260.4% above this industry median. Based on the distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #44 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Xiao Fang Pharmaceutical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Xiao Fang Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #44 out of 960 companies for EBITDA Margin %. This places Shanghai Xiao Fang Pharmaceutical Co in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Shanghai Xiao Fang Pharmaceutical Co's value of 44.94% is 260.4% above this benchmark. Historically, Shanghai Xiao Fang Pharmaceutical Co's own EBITDA Margin % has ranged from 39.88 to 52.86 over the past decade. While the company's 10-year median is 49.96 vs. the industry median of 12.47, Shanghai Xiao Fang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Xiao Fang Pharmaceutical Co's current EBITDA Margin % of 44.94% is 260.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Xiao Fang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Xiao Fang Pharmaceutical Co's current EBITDA Margin % is 44.94%, which is 10% below median its own 10-year median of 49.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Xiao Fang Pharmaceutical Co stock overvalued right now?
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) has a current EBITDA Margin % of 44.94%. The current EBITDA Margin % is 44.94%, which is 10% below median its 10-year median of 49.96 and 260.4% above the Drug Manufacturers industry median of 12.47. Shanghai Xiao Fang Pharmaceutical Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207), the current EBITDA Margin % is 44.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Xiao Fang Pharmaceutical Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603207 has been successfully added to your 
